Talphera, Inc. insider trading
Every open-market purchase and sale by Talphera, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Talphera, Inc.’s insiders pay?
From June 13, 2011 to March 25, 2026, 18 insiders reported 52 open-market purchases and 8 sales not made under a pre-set plan in Talphera, Inc. Twelve months after each purchase was reported, the shares were −27.3% against the S&P 500 on average (median −29.3%), over 6 purchases with a full year of prices; 0% beat the index. After sales, the shares moved −64.2% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on May 30, 2013 into $9,778 by November 2, 2026, −0.2% a year. It held shares 11% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $16,392 (+3.8% a year), and held throughout $57,331 (+13.9%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Edwards Mark G | Director | 13 | −32.0% (1) | 0% | 0 | — | November 12, 2019 |
| Angotti Vincent J. | CHIEF EXECUTIVE OFFICER | 11 | — | — | 0 | — | March 25, 2026 |
| Asadorian Raffi | Chief Financial Officer | 7 | — | — | 0 | — | February 20, 2026 |
| Perceptive Life Sciences Master Fund Ltd | 10% owner | 3 | −28.7% (3) | 0% | 3 | −49.8% (1) | June 21, 2017 |
| Palmer Pamela P | Chief Medical Officer | 4 | — | — | 1 | — | August 25, 2023 |
| Adams Adrian | Director | 2 | −15.7% (1) | 0% | 0 | — | June 15, 2020 |
| Dasu Badri N | Chief Engineering Officer | 2 | — | — | 0 | — | February 20, 2026 |
| Edelman Joseph | 10% owner | 1 | −30.1% (1) | 0% | 1 | — | September 30, 2016 |
| Jaeger Wilfred E | Director | 2 | — | — | 0 | — | December 11, 2012 |
| Perceptive Advisors LLC | 10% owner | 0 | — | — | 2 | — | November 9, 2015 |
| Afable Richard | Director | 1 | — | — | 0 | — | April 23, 2015 |
| Aslam Shakil | Chief Medical Officer | 1 | — | — | 0 | — | February 20, 2026 |
| Hamel Lawrence G | Chief Development Officer | 1 | — | — | 0 | — | March 4, 2019 |
| Hoffman Stephen J | Director | 1 | — | — | 0 | — | May 31, 2012 |
| King Richard | Chief Executive Officer | 1 | — | — | 0 | — | June 13, 2011 |
| Rosen Howard B | CEO | 1 | — | — | 0 | — | May 16, 2016 |
| Wan Mark A | Director | 0 | — | — | 1 | −78.5% (1) | March 11, 2014 |
| Welch James H | Chief Financial Officer | 1 | — | — | 0 | — | September 7, 2011 |
When several insiders traded Talphera, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Talphera, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −2.8% against the index. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| June 28, 2013 | 2 buying | +8.4% | −2.8% | −13.8% |